Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Real-time Estimate Cboe BZX  -  12:21 2022-10-04 pm EDT
139.32 USD   +1.18%
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK (tisotumab vedotin-tftv)
AQ
09/28Zai Lab Strikes Licensing Deal with Nasdaq-listed Seagen for Cervical Cancer Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen Loses Arbitration Against Daiichi Sankyo; Sees No Impact on Existing Business

08/12/2022 | 02:18pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
DAIICHI SANKYO CO., LTD. 3.19% 4237 Delayed Quote.40.38%
SEAGEN INC. 1.19% 139.325 Delayed Quote.-10.93%
All news about SEAGEN INC.
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Zai Lab Strikes Licensing Deal with Nasdaq-listed Seagen for Cervical Cancer Drug
MT
09/27Zai Lab Signs Exclusive Collaboration, License Agreement With Seagen to Develop, Commer..
MT
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
BU
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
CI
09/26Sector Update: Health Care Stocks Fall on Monday
MT
09/26Sector Update: Health Care
MT
09/26Top Midday Gainers
MT
09/26Seagen, Lava Therapeutics Sign License Agreement for Pre-Clinical Asset Targeting Solid..
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 844 M - -
Net income 2022 -639 M - -
Net cash 2022 1 472 M - -
P/E ratio 2022 -39,7x
Yield 2022 -
Capitalization 25 397 M 25 397 M -
EV / Sales 2022 13,0x
EV / Sales 2023 9,36x
Nbr of Employees 2 675
Free-Float 99,1%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 137,70 $
Average target price 183,43 $
Spread / Average Target 33,2%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-10.93%25 397
MODERNA, INC.-52.36%47 331
LONZA GROUP AG-35.56%36 715
IQVIA HOLDINGS INC.-34.00%34 728
ALNYLAM PHARMACEUTICALS, INC.18.03%23 620
CELLTRION, INC.-11.36%16 854